During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 1.44 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stock’s price was $11.76, reflecting an intraday gain of 2.62% or $0.3. The 52-week high for the EYPT share is $30.99, that puts it down -163.52 from that peak though still a striking 51.19% gain since the share price plummeted to a 52-week low of $5.74. The company’s market capitalization is $629.38M, and the average intraday trading volume over the past 10 days was 1.46 million shares, and the average trade volume was 723.19K shares over the past three months.
EyePoint Pharmaceuticals Inc (EYPT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.15. EYPT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.55.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
EyePoint Pharmaceuticals Inc (EYPT) registered a 2.62% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.62% in intraday trading to $11.76, hitting a weekly high. The stock’s 5-day price performance is 23.01%, and it has moved by 43.24% in 30 days. Based on these gigs, the overall price performance for the year is 95.35%. The short interest in EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is 9.17 million shares and it means that shorts have 15.84 day(s) to cover.
The consensus price target of analysts on Wall Street is $30, which implies an increase of 60.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $30 and $30 respectively. As a result, EYPT is trading at a discount of -155.1% off the target high and -155.1% off the low.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Statistics show that EyePoint Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. EyePoint Pharmaceuticals Inc (EYPT) shares have gone down -41.02% during the last six months, with a year-to-date growth rate less than the industry average at -28.02% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -66.70% this quarter and then drop -84.80% in the quarter after that. In the rating firms’ projections, revenue will decrease -9.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.07M as predicted by 12 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 10.14M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 15.2M and 14.03M respectively. In this case, analysts expect current quarter sales to shrink by -33.80% and then drop by -27.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 29.57%. While earnings are projected to return -29.89% in 2024.
EYPT Dividends
EyePoint Pharmaceuticals Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
EyePoint Pharmaceuticals Inc insiders own 1.45% of total outstanding shares while institutional holders control 110.24%, with the float percentage being 111.86%. CORMORANT ASSET MANAGEMENT, LP is the largest shareholder of the company, while 212.0 institutions own stock in it. As of 2024-06-30, the company held over 8.32 million shares (or 15.7334% of all shares), a total value of $72.43 million in shares.
The next largest institutional holding, with 5.18 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 9.7818% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $45.03 million.
